Azathioprine: A guide for the management of dermatology patients

Dermatologic Therapy

Volumn 20, Issue 4, 2007, Pages 206-215

  Wise, Melissa ^a   Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Azathioprine; Dermatology; Thiopurine methyltransferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DERMATOLOGICAL AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISOLONE; PRODRUG; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; TRIAMCINOLONE; WARFARIN;

ACTINIC RETICULOID; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; BEHCET DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BULLOUS PEMPHIGOID; CANCER RISK; CHRONIC ACTINIC DERMATITIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DERMATOLOGY; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHEMA MULTIFORME; FETOTOXICITY; GASTROINTESTINAL ABSORPTION; GENOTYPE; GRAFT VERSUS HOST REACTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LICHEN PLANUS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NAUSEA AND VOMITING; PANCYTOPENIA; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC SYNDROME; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHARMACOGENETICS; PHENOTYPE; PHOTODERMATOSIS; POMPHOLYX; PRACTICE GUIDELINE; PREGNANCY; PSORIASIS; PYODERMA GANGRENOSUM; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SHOCK; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT; VASCULITIS;

ANIMALS; AZATHIOPRINE; HUMANS; METHYLTRANSFERASES; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES;

EID: 35648945354     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00134.x     Document Type: Review

References (88)

1. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993 : 685 : 400 407.
2. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 1961 : 28 : 65 81.
3. Calne RY, Alexandre GP, Murray JE. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann N Y Acad Sci 1962 : 99 : 743 761.
4. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963 : 268 : 1315 1323.
5. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q J Med 2002 : 95 : 439 444.
6. Drug Facts and Comparisons, Azathioprine 2000 : 1549 1550.
7. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998 : 16 : 235 251.
8. Anstey AV, Wakelin S, Reynolds NJ. British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004 : 151 : 1123 1132.
9. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995 : 88 : 155P 160P.
10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 : 32 : 651 662.
11. Corominas H, Domenech M, Laiz A, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 2003 : 42 : 40 45.
12. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999 : 9 : 37 42.
13. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999 : 8 : 367 370.
14. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999 : 9 : 773 776.
15. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999 : 8 : 371 376.
16. Duley JA, Marinaki AM, Arenas M, Florin TH. Do ITPA and TPMT genotypes predict the development of side effects to AZA? Gut 2006 : 55 : 1048.
17. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004 : 14 : 407 417.
18. Menor C, Fueyo JA, Escribano O, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit 2001 : 23 : 536 541.
19. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 : 126 : 608 614.
20. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004 : 41 : 294 302.
21. Cheung ST, Allan RN. Mistaken identity. misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003 : 15 : 1245 1247.
22. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of thiopurine methyltransferase (TPMT) deficiency - a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 2006 : 62 : 473 476.
23. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999 : 38 : 640 644.
24. Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A, Tassaneeyakul W. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 2003 : 76 : 265 266.
25. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992 : 85 : 752 756.
26. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998 : 41 : 1858 1866.
27. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995 : 131 : 193 197.
28. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995 : 133 : 460 462.
29. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988 : 47 : 988 992.
30. Nero P, Rahman A, Isenberg DA. Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? Ann Rheum Dis 2004 : 63 : 325 326.
31. Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP Jr. Hypersensitivity reaction to azathioprine. South Med J 1998 : 91 : 471 474.
32. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996 : 30 : 951 954.
33. el-Gamel A, Evans C, Keevil B, et al. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients. Transplant Proc 1998 : 30 : 1127 1129.
34. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996 : 61 : 1661 1662.
35. Duley JA, Chocair PR, Florin TH. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 2005 : 22 : 1161 1162.
36. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002 : 16 : 79 85.
37. Gossmann J, Kachel HG, Schoeppe W, Scheuermann EH. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993 : 56 : 585 589.
38. Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim- sulfamethoxazole. Ann Intern Med 1980 : 93 : 560 562.
39. Ng HJ, Crowther MA. Azathioprine and inhibition of the anticoagulant effect of warfarin. evidence from a case report and a literature review. Am J Geriatr Pharmacother 2006 : 4 : 75 77.
40. Saway PA, Heck LW, Bonner JR, Kirklin JK. Azathioprine hypersensitivity. Case report and review of the literature. Am J Med 1988 : 84 : 960 964.
41. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006 : 55 : 369 389.
42. Black M, Mignogna MD, Scully C. Number II. Pemphigus vulgaris. Oral Dis 2005 : 11 : 119 130.
43. Mahajan VK, Sharma NL, Sharma RC, Garg G. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases. Int J Dermatol 2005 : 44 : 821 827.
44. Wolff K, Schreiner E. Immunosuppressive therapy of pemphigus vulgaris. Preliminary results of azathioprine (Imuran) treatment. Archiv fur Klinische und Experimentelle Dermatologie 1969 : 235 : 63 77.
45. Roenigk HH Jr., Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol 1973 : 107 : 353 357.
46. Ljubojevic S, Lipozenci J, Brenner S, Budimci D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol 2002 : 16 : 599 603.
47. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003 : 49 : 1059 1062.
48. Lear JT, English JS, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 1996 : 35 : 642 643.
49. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002 : 43 : 125 127.
50. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002 : 147 : 324 330.
51. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006 : 367 : 839 846.
52. Dawe RS, Ferguson J. Diagnosis and treatment of chronic actinic dermatitis. Dermatol Ther 2003 : 16 : 45 51.
53. Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol 1984 : 110 : 691 695.
54. Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 1989 : 121 : 639 646.
55. Yap LM, Foley P, Crouch R, Baker C. Chronic actinic dermatitis: a retrospective analysis of 44 cases referred to an Australian photobiology clinic. Australas J Dermatol 2003 : 44 : 256 262.
56. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003 : 4 : 449 465.
57. Wenzel J, Bieber T, Uerlich M, Tuting T. Systemic treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 2003 : 1 : 694 704.
58. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001 1 CD002954.
59. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991 : 127 : 515 522.
60. Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988 : 19 : 961 965.
61. Roustan G, Salas C, Barbadillo C, Sanchez Yus E, Mulero J, Simon A. Lupus erythematosus with an erythema multiforme-like eruption. Eur J Dermatol 2000 : 10 : 459 462.
62. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985 : 121 : 1323 1325.
63. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002 : 147 : 174 178.
64. Volc-Platzer B, Wolff K. Treatment of subacute cutaneous lupus erythematosus with thalidomide. Hautarzt 1983 : 34 : 175 178.
65. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 1990 : 8 : 355 365.
66. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996 : 34 : 1047 1060.
67. Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangrenosum. Dermatology 2002 : 205 : 221 223.
68. Callen JP, Case JD, Sager D. Chlorambucil - an effective corticosteroid-sparing therapy for pyoderma gangrenosum. J Am Acad Dermatol 1989 : 21 : 515 519.
69. Carp JM, Onuma E, Das K, Gottlieb AB. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease. Cutis 1997 : 60 : 135 138.
70. Batra AK, Levey JM, Trister J, Patwardhan R. Pyoderma gangrenosum in a patient with collagenous colitis. J Am Acad Dermatol 2003 : 49 (5 Suppl S277 S279.
71. Adam DJ, Nawroz I, Petrie PW. Pyoderma gangrenosum severely affecting both hands. J Hand Surg - [Br] 1996 : 21 : 792 794.
72. Byrne JP, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis: report of two cases. Arch Dermatol 1976 : 112 : 1297 1301.
73. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr., White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 2000 : 79 : 37 46.
74. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997 : 137 : 1000 1005.
75. Callen JP. Pyoderma gangrenosum. Lancet 1998 : 351 : 581 585.
76. Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006 : 24 : 414 429.
77. Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J 1987 : 80 : 848 851.
78. Manoharan S, Muir J. Gallbladder vasculitis associated with cutaneous leucocytoclastic vasculitis. Australas J Dermatol 2004 : 45 : 216 219.
79. Jorgensen C, Bologna C, Sany J. Vasculitis and psoriatic arthritis associated with Down's syndrome. Clin Exp Rheumatol 1995 : 13 : 749 751.
80. Hafeez ZH. Unusual presentation of cutaneous vasculitis. Int J Dermatol 1998 : 37 : 687 690.
81. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991 : 151 : 2249 2254.
82. Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003 : 349 : 36 44.
83. Langford CA. Treatment of ANCA-associated vasculitis. N Engl J Med 2003 : 349 : 3 4.
84. Munro DD. Azathioprine in psoriasis. Proc R Soc Med 1973 : 66 : 747 748.
85. Greaves MW, Dawber R. Azathioprine in psoriasis. Br Med J 1970 : 2 : 237 238.
86. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999 : 455 : 343 348.
87. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005 : 23 : 259 300.
88. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987 : 41 : 18 25.